Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Beta-blockers safe for use in ECMO patients

10 Aug 2019

The use of beta-blockers in hypoxaemic patients receiving veno-venous extracorporeal membrane oxygenation (V–V ECMO) safely and modestly increases oxygen saturation, a recent study has found.

Researchers retrospectively examined 33 patients (median age, 49 years; 55 percent male) who received beta-blockers for a median of 4 days while on V–V ECMO. The primary safety outcome was the occurrence of a composite of bradycardia or hypotension requiring intervention, as well as the need for resuscitation, the discontinuation of beta-blockers during the first 5 days and an unexplained spike in serum lactate.

A total of 15 safety events in 13 patients (39 percent) were reported. Majority (n=9) required an increase in norepinephrine dose though only one had to discontinue beta-blocker medication. Other safety endpoints included bradycardia with need for intervention (n=2), new rise in lactate levels (n=2), new septic shock (n=1) and the risk of adverse drug interactions (n=1).

In terms of efficacy, there was a significant increase in oxygen saturation in the first 12 hours after beta-blocker initiation (92 percent to 96 percent; p=0.01) accompanied by a decrease in heart rate (105 to 93 bpm; p<0.01). There were no such changes in lactate levels, norepinephrine dose and mean arterial pressure.

“In our experience, [beta-blocker] therapy was well tolerated and resulted in a significant increase in arterial oxygenation in patients on V-V ECMO,” said researchers. “Future prospective studies should be performed to clarify the benefit of this strategy in this setting.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.